CRDL - Rasio utang marang kapitalisasi buku cardiolrx.com

Cardiol Therapeutics (CRDL) share in the biopharmaceutical sector is constrained by volatility risks and uncertainty surrounding drug registration. The history of debt-to-market capitalization ratios demonstrates financial stability, with the latest value recorded as 0.00. Cardiol Therapeutics is developing safe alternatives to steroids for the treatment of pericarditis, while simultaneously implementing green chemistry principles and optimizing reagent utilization within its laboratories.

This indicator assesses the ratio of total liabilities to the market value of equity. By analyzing the debt-to-market capitalization profile, an investor determines the degree of the business's financial leverage. Low values confirm stability but signal an underutilization of borrowed funds for expansion. For Cardiol Therapeutics (CRDL), such conservatism is justified by the high costs of FDA certification. Patent protection for drugs creates a reliable moat, minimizing the need for risky borrowing.